The grant is specifically intended to support the development of noninvasive, rapid tests that can be used at the point of care in developing country settings.
The test is the first to be approved for the company's second-generation molecular detection system, but can also be run using the first-generation system alongside other existing assays.
The Medicare contractor proposed coverage for several cancer assays, but would not cover molecular respiratory virus assays or a test for inflammatory bowel disease.
The evidence-based guidelines for testing individuals at risk of latent or active TB infection include recommendations on interferon-gamma release and molecular assays.
Researchers have sequenced and analyzed a genome assembly for a Zika virus reference strain from French Polynesia that might be used as part of diagnostic assays.
In Cell this week: analysis of immune microenvironment in hepatocellular carcinoma, proteogenomic analysis of clear cell renal cell carcinoma, and more.
